Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Article Information
vol. 38 no. 7 1181-1188
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 26, 2014
- Accepted March 12, 2015
- Published in print June 23, 2015.
- Published online ahead of print June 6, 2015.
Article Versions
- Previous version (June 6, 2015 - 05:00).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Author Information
- Arthur T. Sands1⇑,
- Brian P. Zambrowicz1,
- Julio Rosenstock2,
- Pablo Lapuerta1,
- Bruce W. Bode3,
- Satish K. Garg4,
- John B. Buse5,
- Phillip Banks1,
- Rubina Heptulla6,
- Marc Rendell7,
- William T. Cefalu8 and
- Paul Strumph1⇑
- 1Lexicon Pharmaceuticals, Inc., The Woodlands, TX
- 2Dallas Diabetes and Endocrine Center, Dallas, TX
- 3Atlanta Diabetes Associates, Atlanta, GA
- 4University of Colorado Denver/Barbara Davis Center for Childhood Diabetes, Aurora, CO
- 5University of North Carolina School of Medicine, Chapel Hill, NC
- 6Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
- 7Creighton Diabetes Center, Omaha, NE
- 8Pennington Biomedical Research Center, Baton Rouge, LA
- Corresponding authors: Arthur T. Sands, arthur.sands{at}bcm.edu, and Paul Strumph, pstrumph{at}lexpharma.com.
Statistics from Altmetric.com
Article usage
In this Issue
July 2015, 38(7)
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
